Study guide

8.5 Patient Confidentiality, HIPAA Privacy & Health-Record Protection

Oklahoma MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 Oklahoma MPJE Format, Blueprint & Passing Standards 1.2 Navigating Oklahoma & Federal Pharmacy Law Hierarchy

2 Chapter 2: State Board Governance & Administrative Framework

2.1 Oklahoma State Board of Pharmacy Structure & Powers 2.2 Disciplinary Procedures, Sanctions & Hearings 2.3 Impaired Pharmacist Recovery Program & Duty to Report

3 Chapter 3: Pharmacist Licensure & Continuing Education

3.1 Pharmacist Licensure Qualifications & Examination Rules 3.2 Reciprocity & Foreign Pharmacy Graduates 3.3 Annual License Renewal & Continuing Education Mandates 3.4 Inactive Status, Late Renewal & License Reinstatement

4 Chapter 4: Pharmacy Interns, Preceptors & Supportive Personnel

4.1 Pharmacy Intern Qualifications & Preceptor Standards 4.2 Experiential Intern Hours, Credit & Board Reporting 4.3 Pharmacy Technician Permitting & Training Requirements 4.4 Pharmacist-to-Technician Ratios & Scope of Supportive Duties

5 Chapter 5: Prescription Validity & Prescriber Authority

5.1 Legal Requirements of a Valid Prescription 5.2 Prescriptive Authority & Scopes of Practice in Oklahoma 5.3 The Pharmacist's Corresponding Responsibility & Red Flags 5.4 Out-of-State, Military & Foreign Prescriptions

6 Chapter 6: Electronic Prescribing & Controlled Substance Schedules

6.1 Oklahoma Electronic Prescribing Mandate (EPCS) 6.2 Federal & Oklahoma Controlled Dangerous Substance Schedules 6.3 Scheduled Listed Chemical Products (SLCP) & Pseudoephedrine Sales 6.4 Schedule V Non-Prescription (Exempt) Controlled Substances

7 Chapter 7: Controlled Substance Dispensing & Opioid Limits

7.1 Schedule II Prescribing & Dispensing Regulations 7.2 Emergency Schedule II Oral Authorizations 7.3 Partial Filling of Schedule II Prescriptions (CARA & Title 63) 7.4 Oklahoma Opioid Prescribing Limits for Acute Pain

8 Chapter 8: Patient Counseling, Safety & Clinical Pharmacy Services

8.1 Patient Counseling Mandates & OBRA '90 8.2 Prospective Drug Utilization Review (DUR) Requirements 8.3 Pharmacist Immunization Administration Authority 8.4 Naloxone Standing Orders, Overdose Prevention & Clinical Protocols 8.5 Patient Confidentiality, HIPAA Privacy & Health-Record Protection

9 Chapter 9: Dispensing Standards, Generic Substitution & Labeling

9.1 Oklahoma Generic Drug Substitution Laws (Orange Book) 9.2 Biosimilar & Interchangeable Biological Products (Purple Book) 9.3 Prescription Refill Limits & Emergency Maintenance Fills 9.4 Prescription Labeling, Poison Prevention Packaging (PPPA) & USP Standards 9.5 Expired, Adulterated, Misbranded & Recalled Drug Products 9.6 Nonprescription Drug Labeling, Packaging & Repackaging 9.7 Returning & Reusing Drugs: Return-to-Stock, Donation & Disposal

10 Chapter 10: Prescription Transfers, Delivery & Monitoring Systems

10.1 Prescription Transfer Rules (Controlled vs. Non-Controlled) 10.2 Oklahoma Prescription Monitoring Program (OK PMP / PMP AWARxE) 10.3 Central Fill, Mail-Order & Prescription Delivery Regulations 10.4 Automated Dispensing Systems (ADS) & Remote Pharmacy Services

11 Chapter 11: Pharmacy Permits, Facilities & Operational Standards

11.1 Oklahoma Pharmacy Licenses & Permits 11.2 Pharmacist-in-Charge (PIC) Governance & Requirements 11.3 Physical Plant, Security & Sanitation Standards 11.4 Pharmacy Permanent Closing & Change of Ownership

12 Chapter 12: Controlled Substance Management, Ordering & Security

12.1 Pharmacy DEA & OBNDD Registration Requirements 12.2 Controlled Substance Ordering (DEA Form 222 & CSOS) 12.3 Controlled Substance Physical Inventory Requirements 12.4 Theft, Significant Loss & CDS Destruction (DEA Form 106 & Form 41)

13 Chapter 13: Compounding Standards & Institutional Practice

13.1 Non-Sterile (USP <795>) & Sterile (USP <797>) Compounding 13.2 Hazardous Drug Handling (USP <800>) 13.3 Hospital & Institutional Pharmacy Operations (Hospital Pharmacies & Drug Rooms) 13.4 Nuclear, Charitable & Specialty Pharmacy Standards

8.5 Patient Confidentiality, HIPAA Privacy & Health-Record Protection

Key Takeaways Explain This Topic AI

NABP competency 2.5 makes "protecting patient and health record confidentiality" an explicitly tested subject, and it is examined alongside Oklahoma-specific confidentiality rules, not just HIPAA in the abstract.

The HIPAA Privacy Rule permits use and disclosure of PHI for treatment, payment, and health care operations without patient authorization, but the minimum necessary standard does not apply to disclosures to a provider for treatment.

OK PMP data carries its own confidentiality regime under 63 O.S. § 2-309D: the central repository information is confidential, is not subject to open-records disclosure, and unauthorized access or disclosure carries criminal and licensure consequences.

A prescription is the property of the patient under 59 O.S. § 354, and no pharmacist may refuse a patient request to transfer it or to supply a reference copy.

Last updated: August 2026

8.5 Patient Confidentiality, HIPAA Privacy & Health-Record Protection

Why this is tested: NABP Competency Statement 2.5 ("Regulations and agencies regarding pharmacy practice") lists "protecting patient and health record confidentiality" as an explicit sub-topic inside the 33% Pharmacist Practice area. Confidentiality questions on the Oklahoma MPJE are rarely pure HIPAA trivia — they usually ask which of three overlapping regimes governs a specific disclosure.

  • 1. The Three Overlapping Regimes +---------------------------------------------------------------------------+
  • | 1. HIPAA (federal) Protected Health Information (PHI) held by |
  • | 45 CFR Parts 160/164 a covered entity; floor, not a ceiling |
  • +---------------------------------------------------------------------------+
  • | 2. OK PMP confidentiality Central repository CDS dispensing data; |
  • | 63 O.S. 2-309D statutorily confidential; criminal penalties |
  • +---------------------------------------------------------------------------+
  • | 3. Oklahoma Board rules Patient records (OAC 535:15-3-14), pharmacy |
  • | OAC Title 535 security, and prescription ownership (354) |
  • +---------------------------------------------------------------------------+

HIPAA sets a federal floor . Where Oklahoma law is more protective — as it is for PMP data — the stricter standard governs, exactly as the Stricter Standard Rule from section 1.2 predicts.

2. HIPAA: What a Pharmacy Actually Must Do

A community pharmacy is a covered entity because it transmits health information electronically in connection with a HIPAA standard transaction (electronic claims adjudication). That triggers a discrete set of obligations:

Obligation Practical form in a pharmacy

Notice of Privacy Practices (NPP) Posted in the pharmacy and provided to the patient; a good-faith effort to obtain written acknowledgment of receipt must be made

  • Privacy Officer A designated individual responsible for the privacy program
  • Workforce training Documented training for pharmacists, interns, technicians, and clerks

Business Associate Agreements (BAAs) Required with software vendors, billing services, reverse distributors handling PHI, and shredding contractors

Safeguards Physical (counseling away from the queue, screens turned from public view, secured will-call bins), administrative, and technical

  • Right of access Patient may inspect and obtain a copy of their records, generally within 30 days
  • Accounting of disclosures Patient may request a list of certain non-TPO disclosures
  • Disclosures permitted without patient authorization

Treatment, Payment, and Health care Operations (TPO). Faxing a profile to the prescriber, adjudicating a claim, and internal quality review all proceed without authorization.

To the individual who is the subject of the PHI.

Public health activities , including reporting adverse events to VAERS and vaccine doses to the Oklahoma State Immunization Information System (OSIIS) .

Required by law — including a subpoena that satisfies the Privacy Rule's conditions, a Board of Pharmacy inspection, and PMP reporting.

Health oversight activities by the OSBP, OBNDD, and DEA.

Disclosures that require authorization

Marketing communications and any sale of PHI.

Psychotherapy notes (rarely relevant in a pharmacy, but tested).

Most disclosures to an employer, a life insurer, or a family member acting outside the patient's expressed or inferred agreement.

The minimum-necessary trap

The minimum necessary standard requires a covered entity to limit PHI to the least amount needed to accomplish the purpose — but it has express carve-outs. Minimum necessary does NOT apply to:

  • Disclosures to or requests by a health care provider for treatment purposes ;
  • Disclosures to the individual ;
  • Uses or disclosures made pursuant to a valid authorization ;
  • Disclosures to HHS for compliance investigations;

Uses or disclosures required by law .

A pharmacist who sends a full medication profile to a treating physician has not violated minimum necessary, because treatment disclosures are exempt.

Breach notification

Under the Breach Notification Rule, an impermissible use or disclosure is presumed to be a breach unless the covered entity demonstrates a low probability that PHI was compromised through a four-factor risk assessment (nature and extent of the PHI, the unauthorized person, whether PHI was actually acquired or viewed, and the extent of mitigation). Notification obligations:

  • Recipient Deadline
  • Affected individuals Without unreasonable delay, no later than 60 days from discovery
  • HHS — breach affecting 500 or more individuals Contemporaneously, no later than 60 days
  • Prominent media in the state/jurisdiction — 500 or more residents No later than 60 days
  • HHS — breach affecting fewer than 500 Annual log, within 60 days after the end of the calendar year

Classic pharmacy scenario. A technician hands a completed prescription bag to the wrong patient at the register, who opens it and reads the label before returning it. That is an impermissible disclosure. The pharmacy must run the four-factor assessment — the PHI was actually viewed, so the presumption of breach is difficult to rebut, and individual notification is likely required.

3. Oklahoma PMP Data: Stricter Than HIPAA

63 O.S. § 2-309D governs the central repository and it is materially more restrictive than the HIPAA baseline:

Repository information is confidential and is not subject to open-records disclosure .

Access is limited to enumerated categories of authorized users — the practitioner or dispenser treating the patient, designated staff acting for them, licensing boards, and law enforcement pursuant to an active investigation.

Unauthorized access, disclosure, or misuse is a criminal offense and independent grounds for Board discipline.

A registrant who checks the repository must note the check in the patient file .

OBNDD may make an unsolicited notification to a pharmacist's or practitioner's licensing board when a patient has received controlled substances in quantities or with a frequency inconsistent with generally recognized standards of safe practice. That notification is itself confidential and may not disclose information protected by the section.

The practical rule for a pharmacist: you may query the PMP for a patient you are dispensing to. You may not query it out of curiosity, for a family member, for an employee, or for a co-worker. "I looked up my neighbour" is the fact pattern that ends careers.

4. Oklahoma Board Rules Touching Confidentiality

Prescription ownership (59 O.S. § 354): "A prescription is the property of the patient for whom it is prescribed." No pharmacist may refuse, on the patient's request in person or through an authorized pharmacist, to transfer the prescription or to supply a reference copy in writing or by telephone. No prescriber may refuse a patient's request to have a prescription transmitted to the pharmacy of the patient's choice. A pharmacy cannot use "we don't release records" to hold a patient hostage.

Patient records (OAC 535:15-3-14): the pharmacy must obtain, record, and maintain the patient profile that makes prospective DUR possible — and must keep it secure and readily retrievable for Board review.

Personnel identification (OAC 535:15-3-2(e)): technicians, auxiliary personnel, and interns must wear tags reading "Rx Tech," "Tech," "Clerk," or "Intern," and must identify themselves as such on any phone call. This is a confidentiality-adjacent rule: a caller must be able to tell whether the person receiving clinical information is a pharmacist.

Impaired-pharmacist program confidentiality: participation records in the peer-assistance program are handled confidentially, which is what makes voluntary self-referral viable (see section 2.3).

5. Exam Decision Path

When a question asks whether a disclosure is permitted:

Is it PMP data? If yes, apply 63 O.S. § 2-309D — authorized users only, for a patient of record. Stop.

Is the recipient the patient, or a provider for treatment? If yes, permitted, and minimum necessary does not apply .

Is it payment or health care operations? Permitted, but minimum necessary does apply.

Is it required by law, public health, or health oversight (OSBP/OBNDD/DEA)? Permitted.

Anything else — marketing, sale, employer, curiosity — requires a valid written authorization .

If the disclosure already happened impermissibly , run the four-factor breach assessment and apply the 60-day notification clock.